300361 Jiangsu Aosaikang Pharmaceutical
- 0.00
- 0.000.00%
Jiangsu Aosaikang Pharmaceutical News
Aosaikang Pharma's Unit Gets Nod to Market Isavuconazole Sulfate for Injection
Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Jiangsu Aosaikang Pharmaceutical, obtained a drug registration certificate from China's National Medical Products Administration for its isavucona
Express News | Osecon: The subsidiary obtained a drug registration certificate for injectable isaconazole sulfate
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
Osecon (002755.SZ): net loss of 149 million yuan in 2023
On April 28, Ge Longhui (002755.SZ) released its 2023 annual report. During the reporting period, the company's operating income was 1,443 million yuan, a year-on-year decrease of 22.92%; net loss attributable to shareholders of listed companies was 149 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 227 million yuan; basic loss per share was 0.16 yuan/share.
Osecon (002755.SZ) announced first-quarter results, net profit of 31.5547 million yuan, turning a loss into a profit
According to Zhitong Finance App News, Osecon (002755.SZ) released its report for the first quarter of 2024. The company's operating income was 448 million yuan, up 32.47% year on year; net profit attributable to shareholders of listed companies was 31,5447 million yuan, which turned a loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.361 million yuan; basic income per share was 0.03 yuan/share.
Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healt
Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healthcare collectively strengthened.
Osecon (002755.SZ): The subsidiary will present clinical research data for the innovative drug ASKC202 at the 2024 AACR Annual Meeting
Gelonghui, April 8, 丨 Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, first announced phase I (ASKC202-001) dose-increasing clinical trial data in the form of a poster at the American Association for Cancer Research (AACR) annual meeting on April 8, 2024.
The innovative medicine sector rebounded and Osecon rose or stopped
Gelonghui, March 27 | Osecon rose and stopped, and Xiangxue Pharmaceutical, First Pharmaceutical Holdings, Yakshi Technology, and Chengdu Pioneer followed suit. According to the news, at the 2024 Annual Meeting of the China Development High-Level Forum held a few days ago, major industry experts said that the development of China's biomedical industry already has a good foundation, and an ecological environment encouraging the development of innovative drugs is being formed.
A-share innovative drug concept stocks fell, and Osecon fell more than 4%
Gelonghui, March 18 | Osecon fell more than 4%, Sailong Pharmaceutical and Baiyunshan fell more than 3%, and Luoxin Pharmaceutical and Pharmaceutical Kangde followed suit.
Express News | Osecon: The subsidiary obtained a notice of acceptance of the application for drug registration and marketing approval for injectable delafloxacin.
Osecon (002755.SZ) issued an advance loss. It is expected to lose a huge loss of 140 million yuan to 200 million yuan in 2023, and the loss will narrow
Osecon (002755.SZ) released the 2023 annual performance forecast, and the company expects 2023 to fall under the above...
Express News | Osecon: Subsidiary dexlansoprazole, etrapoprazole ethanolamine, and torrimifene citrate approved for marketing
Express News | Osecon: Phase III study of the bioinnovative drug ASKB589 completed its first patient administration in China
Osecon (002755.SZ): Subsidiary torimifene citrate tablets obtained drug registration certificate
Gelonghui, January 22丨Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for torimifene citrate tablets approved and issued by the State Drug Administration. Toremifene is a non-steroidal tristyrene derivative that binds to estrogen receptors in a competitive manner with estrogen to prevent cancer cells from growing. Toremifene citrate tablets were developed by KYOWA KIRIN in Japan, and the trade name is FARESTON (FARESTON). China Pharmaceutical Industry Information Center PDB Drug Comprehensive Count
Express News | Osecon: The innovative drug ASKB589 has good safety and tolerability
Osecon (002755.SZ) subsidiary announces the latest research results of the innovative drug ASKB589 at the American Society of Clinical Oncology Symposium
Osecon (002755.SZ) announced that AskGene Limited, a subsidiary of the company...
Osecon (002755.SZ) subsidiary etrapopa ethanolamine tablets obtained a drug registration certificate
Zhitong Finance App News, Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for etrapoethanolamine tablets approved and issued by the State Drug Administration. The relevant indications are: This product is suitable for adults with chronic immune (idiopathic) thrombocytopenia (ITP) patients with chronic immune (idiopathic) thrombocytopenia (ITP) in children aged 6 and above who have previously had poor response to corticosteroids, immunoglobulins, etc. This product is only used in ITP patients with increased risk of bleeding due to thrombocytopenia and clinical conditions.
Osecon: New specifications for subsidiary pipericillin capsules approved for listing
Gelonghui, December 15 | Osaikang announced that Jiangsu Osaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the “Notice of Approval of Supplemental Drug Applications” for pipericillin capsules issued by the State Drug Administration, agreeing to increase the 75mg and 100mg specifications for the company's pipericillin capsules to the existing 125 mg specifications, and to issue new drug approval numbers.
Osecon (002755.SZ): The subsidiary's innovative drug ASKC202 tablets and ASK120067 tablets were approved for clinical trials
Gelonghui (002755.SZ) announced that the clinical trial of ASKC202 tablets combined with ASK120067 tablets reported by Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“subsidiary”), a wholly-owned subsidiary of the company, recently received a clinical trial approval notice issued by the State Drug Administration. The combined use of ASKC202 tablets and ASK120067 tablets will conduct an open, multi-center, I evaluation of the safety, tolerability, pharmacokinetic characteristics and initial efficacy of ASKC202 tablets in patients with advanced solid tumors Phase clinical trials.
Osecon (002755.SZ): Temozolomide capsules obtained a drug registration certificate
Osaikang (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received...
Analysis
Price Target
No Data
